Upgrade to SI Premium - Free Trial

Eli Lilly & Co. (LLY) Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Meets Primary Endpoint

April 24, 2017 6:46 AM
Eli Lilly and Company (NYSE: LLY) today announced that following a pre-planned interim analysis for MONARCH 3, the trial met ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles